Cytarabine ocfosfate

Drug Profile

Cytarabine ocfosfate

Alternative Names: ara CMP stearyl ester; C 18 PCA; Cytarabine phosphate stearate; Estarabine; Phosteabine sodium; Starasid; YNK 01

Latest Information Update: 09 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Kayaku; Yamasa Corporation
  • Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Leukaemia
  • Discontinued Cancer

Most Recent Events

  • 06 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 29 Nov 2000 A phase II study has been added to the Cancer therapeutic trials and adverse events sections
  • 06 May 1997 Launched for Leukaemia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top